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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S152Figure 2. Applying the injectable plasters in a full thickness chondral
defect during an arthroscopic procedure. Before (A) and after (B) the
injection of the plaster. The initial ﬂuidity ensures complete ﬁlling of the
defect. The plaster remained ﬁxed at the defect site after manual ﬂexion of
the joint.
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USE OF HYALURONAN SCAFFOLD IN COMBINATION WITH FRESH
BONE MARROW TRANSPLANTATION OR WITH MICROFRACTURES
IN TREATMENT OF CARTILAGE DEFECTS OF THE KNEE JOINT
K. Slynarski y, J.M. Deszczynski, Jr. z,y, R. Jopowicz z,y, A. Krzesniak y.
y Lekmed Med. Ctr., Warsaw, Poland; zWarsaw Med. Univ., Warsaw,
Poland
Purpose: Microfracture is a well-established procedure in cartilage
knee surgery. Currently there are many different techniques utilizing
biological implants to support the chondrogenesis. The purpose of
this study is to evaluate the medium-term results of the hyaluronic
scaffold in combination with fresh bone marrow transplantation or
with microfractures in treatment of cartilage defects of the knee
joint.
Methods: A new type of hyaluronic acid membrane Hyalofast (Anika
Therapeutics, Inc. MA, USA) was used as a CHONDROINDUCTIVE
SCAFFOLD that allows attachment and stimulation of mesenchymal
stem cells of bone marrow. In study group we used hyaluronan scaffold
with fresh bone marrow transplantation and in control group the
scaffold was combined with microfractures. Patients were followed
using a Socrates Orthopeadic Outcome Software (Ortholink Pty Ltd,
Australia) database tool to track changes in function and symptoms by
the Lysholm, Tegner and VAS scores along with MRI imaging.
Results: 40 Patients met the inclusion criteria for this study. Both
groups consisted of 20 patients. All defects was grade IIIA (n ¼ 10) and
IIIB (n¼ 20) according to the ICRS classiﬁcation. The mean defect size of
the chondral lesions was 2.7 cm (2) (range 1,4–3,1). Defects were
localized at the medial (n ¼ 12) and lateral (n ¼ 8) condyle, at the
trochlea (n ¼ 12) and at the patella ¼ (8). Based on the imaging eval-
uation a satisfactory outcome was observed in all cases at estimated
intervals. Signiﬁcant improvement (P ¼ 0,002, wilcoxon rank-sum test)
was observed in Lysholm (preop ¼ 61,2 ; 1 year postop ¼ 82,3; 2 year
postop ¼ 85,3) Tegner improvement (2,7) and VAS scores. All patients
returned to sport activities which they performed before the surgery.
No adverse effects related to the implant were observed during the
duration of the study. There was no statisctical difference (p ¼ 0,08) in
the results between both groups.
Conclusions: The use of hyaluronic acid membrane is considered to be
safe and effective procedure for treatment of symptomatic chondral
defects of the knee. The data shows that there is no difference between
two techniques of utilizing mircofractues or bone marrow trans-
plantation at the defect site. However, further studies with long-term
follow-up are needed to determine if the grafted area will maintain
structural and functional integrity over time.
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OSTEOARTHRITIS GRADE AND DECISION MAKING IN CARTILAGE
REPAIR
M. Hurtig. Univ. of Guelph, Guelph, ON, Canada
Objective: A recent survey of surgeons that perform microfracture
demonstrated that there is a wide variation in technique(1). We alsoobserved that experienced surgeons performing microfracture in
cadaveric knees improvised or modiﬁed the technique to accommodate
sclerotic or osteopenic bone as well as curved surfaces. One concernwas
that the obtuse approach angle used to approach a surface curving away
from the surgeon created a furrow-like elongated hole along the joint
surface_ we called this, plowing“. The objective of this expeirment was
to determine if plowing affected the integrity of the subchondral bone
plate.
Methods: Forty-two 10 x 10 x 15 mm cubes were cut from the lateral
femoral condyles of human cadaveric knees. MicroCT (45 micron
resolution) was used to characterize the trabecular bone and sub-
chondral bone plate before and after microfracture. Cubes were potted
and underwent non-destructive testing (a 0.25% pre-strain at a strain
rate of 0.01s-1 (move relative) was applied followed by a dynamic
sinusoid of amplitude; 0.05%, frequency; 1Hz, and 20 cycles). Four
microfracture holes were created with a 20o awl (Arthrex, Naples FL)
at 70, 55 and 40 degrees to the joint surface. After non-destructive
testing was repeated all samples underwent compressive testing to
failure using preload of 30N and a rate of 0.01s-1 to a peak strain of
25%.
Results: Microfracture signiﬁcantly reduced the stiffness of sub-
chondral bone (p< .0.025 T-Test) but therewas no effect of awl angle on
subchondral bone stiffness after microfracture. (p < .77, paired T-test).
Failure was through barreling and outward displacement of trabeculae
than than through through the microfracture holes (2/42 samples).
Conclusions: Microfracture reduced the mechanical properties of the
supporting bone in this simpliﬁed protocol regardless of awl approach
angle. Bone compaction frommicrofracture is considered deleterious so
,plowing“ should be discouraged. Creating additional microfracture
holes spaced more closely together than currently recommended
should be done with caution because bone stiffness would be incre-
mentally affected.
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USE OF A SURGICAL HEMOSTAT MODULATES PROPERTIES OF CLOT
ASSOCIATED WITH SUBCHONDRAL BONE MICRODRILLING IN AN
OVINE MODEL FOR CARTILAGE REPAIR
M. Long y, M. Hawkins z. y Stryker Orthobiologics, Mahwah, NJ, USA;
z Stryker Joint Preservation, Mahwah, NJ, USA
Purpose: Since the properties of the clot formed in microfracture
therapy are inﬂuential to clinical outcome, we aimed to evaluate
whether the use of a surgical hemostat (SH) to control bleeding and
augment and stabilize the microfracture clot would improve the clot
properties in the cartilage defects.
Methods: Twenty sheep were operated and cared for at Thomas D.
Morris (Reisterstown, MD) under IACUC approval #12-038 and GLP
quality controls. Two full thickness chondral defects were created in the
distal part of the femur: one 8mmx10mm in the medial femoral con-
dyle; one 6mmx12mm in the trochlea. Each defect was treated by
microfracture/microdrilling (MFX - MicroFX OCD, Stryker) and alter-
natively treated with a surgical hemostat containing autologous
plasma, pepsinized microﬁbrillar collagen and recombinant thrombin
(SH - VITAGEL RT Surgical Hemostat, Stryker). The hemostat was
prepared individually for each treated defect per manufacturer’s
instructions for use. SH was applied to the defect once a bleeding bed
was achieved at the bottom of the defect in sufﬁcient volume (z0.2-
0.4cc) to ﬁll the entire defect, and was then allowed to congeal. Time to
hemostasis when bleeding stopped was measured starting at the time
when the hemostat was applied. The joint was closed once bleeding /
oozing was completely stopped. The sheep were placed in a Thomas
splint for 2 week post-op. Clot/cartilage ﬁll was visually evaluated (non-
instrumented). Clot/cartilage stiffness was assessed semi-quantitatively
using a ﬂexible #10 scalpel blade probewith a 0-4 scoring relative to the
surrounding intact cartilage. Time 0 and 2 weeks clots were carefully
harvested from the defects and sliced in three samples, when allowed
by the size of the clot samples, for subsequent histology/histochemistry,
biochemistry (ELISA for GAG, COL I & II), and DNA/Cellularity (RT-PCR
for COL I & II, Aggrecan) evaluations. For clot and cartilage histology/
histochemistry, frozen and decalciﬁed sections, respectively, were
processed and slides stained with H&E and Safranin-O, and immunos-
tained for Collagen I and II.
Results: Subchondral bone bleeding/marrow stimulation was achieved
in all defects. Time to hemostasis was signiﬁcantly reduced by 52%
when SH was used with MFX (369 vs. 776 seconds, p < 0.01). SH clots
were signiﬁcantly stiffer once hemostasis was achieved (Time 0, 1.9 vs.
1.0, p < 0.001), continued trending to greater stiffness 2 weeks post-op,
with no difference at 24 weeks (Fig. 1). Defect ﬁll was signiﬁcantly
increased 2 weeks post-op when SH was applied (64% vs. 49%, p < 0.05,
Fig. 2), but no difference was observed at 24 weeks. After 2 weeks,
visually, the majority of SH clots appeared glossy white, suggesting
ﬁbrocartilage formation. Overall clot histology at 2 weeks showed
preliminary, incomplete maturation of the clot with no apparent
organized structure, as expected after this short in vivo period. One SH
sample histologically exhibited a substantial matrix formationsurrounding cells with evidence of lacunae formation and evidence of
collagen II formation, suggesting the early stage of ﬁbrocartilage for-
mation (Fig.3). Biochemistry analysis was overall inconclusive. RT-PCR
analysis showed an increase in Collagen I, and to a lesser extent in
Collagen II, after 2 weeks in vivo. When samples were compared in the
same animals (N ¼ 2), the SH group exhibited higher Collagen I and II
signal intensity than the MFX group. Aggrecan analysis was incon-
clusive, as well as the 24 weeks results. After 24 weeks, visually, all
defects appeared mostly ﬁlled with a glossy white tissue comparable to
the untouched surrounding cartilage, suggesting cartilage formation.
The trochlea defects exhibited a higher degree of ﬁll than the condyle
defects. No distinct difference was observed between the two groups at
this late stage of cartilage repair. Histology/histochemistry evaluations
will be used to detect any micro-differences between the two groups.
Conclusions: Under the conditions of the present animal study, the use
of a surgical hemostat containing autologous plasma, pepsinized
microﬁbrillar collagen, and recombinant thrombin in microfracture/
microdrilling defects provided hemostasis but also suggested improved
properties of the clot towards the early stage of cartilage repair. While
microdrilling alone resulted in some positive outcome due to sub-
stantial and uniform bleeding for all defects, the amount of clot tissue in
the defect, clot stiffness, clot biochemistry and cellular organization
were all improved in the early stage of cartilage repair when the
hemostat was used.
Figure 1. Clot stiffness (semi-quantitative) at Time 0, 2, and 24 weeks for
both MFX and SH groups.
Figure 2. Defect Fill (non-instrumented visual evaluation) observed after
2 and 24 weeks in vivo.
